Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $36.82.
A number of research firms have issued reports on AVTX. Cantor Fitzgerald reissued an “overweight” rating on shares of Avalo Therapeutics in a research report on Wednesday, September 16th. Oppenheimer set a $16.00 price objective on Avalo Therapeutics in a report on Monday, October 26th. HC Wainwright downgraded Avalo Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, October 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Wednesday, November 4th. Finally, Wall Street Zen upgraded Avalo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 7th.
View Our Latest Stock Report on Avalo Therapeutics
Insider Activity
Institutional Investors Weigh In On Avalo Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Nantahala Capital Management LLC lifted its position in shares of Avalo Therapeutics by 15.0% in the 3rd quarter. Nantahala Capital Management LLC now owns 2,142,308 shares of the company’s stock worth $32,842,000 after buying an additional 280,058 shares during the last quarter. Braidwell LP bought a new stake in shares of Avalo Therapeutics during the 2nd quarter valued at about $30,107,000. Affinity Asset Advisors LLC raised its stake in Avalo Therapeutics by 27.6% during the first quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock worth $20,019,000 after acquiring an additional 289,786 shares during the period. Seven Fleet Capital Management LP raised its stake in Avalo Therapeutics by 34.3% during the second quarter. Seven Fleet Capital Management LP now owns 770,765 shares of the company’s stock worth $14,244,000 after acquiring an additional 196,882 shares during the period. Finally, Bank of America Corp DE raised its stake in Avalo Therapeutics by 3.5% during the first quarter. Bank of America Corp DE now owns 643,000 shares of the company’s stock worth $9,600,000 after acquiring an additional 21,650 shares during the period. Institutional investors own 87.06% of the company’s stock.
Avalo Therapeutics Stock Performance
AVTX stock traded up $0.06 during midday trading on Friday, hitting $7.76. 974,092 shares of the stock were exchanged, compared to its average volume of 3,339,771. The stock’s 50-day moving average price is $12.33 and its 200-day moving average price is $15.64. The stock has a market cap of $448.68 million, a price-to-earnings ratio of -3.08 and a beta of 0.75. Avalo Therapeutics has a fifty-two week low of $6.53 and a fifty-two week high of $24.27.
Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.25. Research analysts anticipate that Avalo Therapeutics will post -2.52 EPS for the current year.
About Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated and inflammatory diseases. The company does not have marketed products and is centered on advancing drug candidates through clinical development. Its lead candidate, AVTX-009, is a monoclonal antibody that targets interleukin-1 beta (IL-1β), an inflammatory signaling protein. Avalo is developing the therapy for hidradenitis suppurativa, a chronic inflammatory skin disease, and has described potential applications in other inflammatory conditions.
See Also
- Five stocks we like better than Avalo Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
